On Wednesday shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB) closed at $5.94. Company’s sales growth for last 5 years was 260.20% and EPS growth for next 5 years is recorded as 30.00%. On March 23, Pacific Biosciences of California, Inc. (NASDAQ:PACB) announced that the company has launched a Certified Service Provider (CSP) program and added new informatics partners to meet the increasing demand for Single Molecule, Real-Time (SMRT®) Sequencing and data analysis worldwide.
National Bank of Greece (ADR) (NYSE:NBG) in last trading activity fell -3.12% to close at $1.24. Company weekly performance is -8.82% while its quarterly performance stands at -30.73%. National Bank of Greece (ADR) (NYSE:NBG) is -78.58% away from its 52 week high. On 23 March 2015, National Bank of Greece (ADR) (NYSE:NBG) unveiled changes to its top management, after the lender’s chairman and chief executive officer resigned. Ex-Labor Minister Louka Katseli was named chairman, succeeding George Zanias.
On last trading day Books-A-Million Inc. (NASDAQ:BAMM) increased 0.73% to close at $2.76. Its volatility for the week is 3.76% while volatility for the month is 2.29%. BAMM’s sales growth for past 5 years was -1.80% and its EPS growth for past 5 years was -22.50%. Books-A-Million Inc. (NASDAQ:BAMM) monthly performance is 5.34%. Books-A-Million, Inc. (NASDAQ:BAMM) on 23 March 2015, announced financial results for the 13-week and 52-week periods ended January 31, 2015. Revenues for the 13-week period ended January 31, 2015 increased 1.8% to $160.8 million, compared with revenues of $158.0 million in the 13-week period ended February 1, 2014.
Heartware International Inc. (NASDAQ:HTWR) has 0.70% insider ownership. In last trading activity company’s stock closed at $87.23. TheStreet upgraded shares of HeartWare International (NASDAQ:HTWR) from a sell rating to a hold rating in a report released on 26 March 2015.
On last trading day Nymox Pharmaceutical Corporation (NASDAQ:NYMX) increased 49.64% to close at $1.26. Its volatility for the week is 27.77% while volatility for the month is 18.76%. NYMX’s sales growth for past 5 years was 53.40% and its EPS growth for past 5 years was 1.40%. Nymox Pharmaceutical Corporation (NASDAQ:NYMX) monthly performance is 99.52%.Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced that the Company is undertaking further analyses of its pivotal U.S. Phase 3 studies of NX-1207 for prostate enlargement (BPH). This will include new long-term data from Studies NX02-0017 and NX02-0018. The Company expects to provide these new pivotal Phase 3 study results in Q2 or early Q3 this year.